Business
-
Amphastar Pharmaceuticals will pay Eli Lilly $500 million up front, an additional $125 million after one year, and up to $450 million in sales milestone payments for the rights to Baqsimi intranasal dry powder glucagon. The company… Read more . . .
-
Ritedose Corporation, which says that it is the largest manufacturer of albuterol sulfate inhalation solution in the US, announced that it has begun compounding 5 mg/ml albuterol sulfate inhalation solution ampules through the 503B manufacturing process in response… Read more . . .
-
Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL.… Read more . . .
-
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company’s AER-01 inhaled mucolytic for the treatment of COPD, the company… Read more . . .
-
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID.… Read more . . .
-
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company’s Gimoti metaclopramide nasal spray until 2030. The patent (No.… Read more . . .
-
Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement… Read more . . .
-
Liquidia Corporation said that a new agreement will supersede its 2012 license agreement with GSK that gave GSK exclusive rights to develop certain inhaled formulations based on Liquidia’s PRINT particle engineering technology. In 2015, GSK exercised… Read more . . .
-
DPI developer PureIMS announced that it has closed an investment round that included Boost-UP Foundation, CardusoCapital, IMDS Medical Devices, and LinesBridge Pharma Group, with funds intended mostly to support development of a levodopa DPI based… Read more . . .
-
Catalent and Harm Reduction Therapeutics (HRT) announced that they have signed a commercial supply agreement for the manufacture of HRT’s RiVive intranasal naloxone. The news comes shortly after HRT said that it would receive an… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan